Share Prices & Company Research

Stockbroking

PureTech Health

Current Price 157.50p Bid 157.50p Ask 162.50p Change 1.29%
Last Updated: 24/06/2018 13:53. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

PureTech Health plc is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the BIG axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, the Company is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies that includes two pivotal stage programmes, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programmes. PureTech's rich research and development pipeline has been advanced in collaboration with some of the world's leading scientific experts, who along with PureTech's team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent, and clinically de-risk new medicines. With this experienced team pursuing cutting edge science, PureTech Health is building the biopharma company of the future focused on improving and extending the lives of people with serious disease.

Financial Highlights Year Ended 31/12/2017

Turnover
£2.54m
Operating Profit
£-115.42m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-11.96

Key Personnel

Daphne Zohar
Chief Executive Officer
Stephen Muniz
Finance Director
Joichi Ito
Non-Executive Chairman
Dr Bennett Michael Shapiro
Non-Executive Director
Marjorie Morris Scardino
Non-Executive Director
Dr Robert Langer
Non-Executive Director
Dr Raju Kucherlapati
Non-Executive Director
Dr John LaMattina
Non-Executive Director
Christopher Viehbacher
Non-Executive Director

Stock Details

EPIC
PRTC
ISIN
GB00BY2Z0H74
Shares in Issue
282,429,696
Market cap
£439.18m

Analyst Views (4)

Strong Buy
 
100.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
157.50p
Bid Price
157.50p
Ask Price
162.50p
Volume
12867
Change Today
2.00p
% Change Today
1.29%
Open
162.50p
Previous Close
157.50p
Intraday High
162.50p
Intraday Low
154.50p
52 Week High
182.50p
52 Week Low
115.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

PureTech Health Intra-day Chart

PureTech Health News

News in this section is provided by MoneyAM

Broker Forecast - Jefferies International issues a broker note on PureTech Health Plc 09 May 2018 | 12:00 Broker Forecast - Peel Hunt issues a broker note on PureTech Health Plc 09 May 2018 | 10:40 PureTech Health operating losses deepen on higher R&D spend 16 Apr 2018 | 08:09 PureTech Health affiliate appoints new CEO 09 Apr 2018 | 07:14 Director Deals - PureTech Health Plc (PRTC) 15 Mar 2018 | 09:00 Director Deals - PureTech Health Plc (PRTC) 14 Mar 2018 | 10:15 Broker Forecast - Peel Hunt issues a broker note on PureTech Health Plc 26 Jan 2018 | 10:40 PureTech affiliate resTORbio prices $85.0m IPO 26 Jan 2018 | 07:18 PureTech affiliate appoints new director 03 Jan 2018 | 09:14 PureTech Health affiliate to launch IPO 02 Jan 2018 | 09:54 FTSE 100 follows US higher on potential tax reform 19 Dec 2017 | 09:09 PureTech Health announces affiliate's research collaboration with Eli Lilly 19 Dec 2017 | 07:51 PureTech Health company granted US patents 13 Dec 2017 | 10:02 PureTech microbiome programme enters Phase 1 trial 07 Dec 2017 | 09:30 PureTech company files for IPO 05 Dec 2017 | 09:46 Broker Forecast - Numis issues a broker note on PureTech Health Plc 04 Dec 2017 | 13:20 US tax cut approval in Senate pushes FTSE higher 04 Dec 2017 | 11:52 Broker Forecast - Peel Hunt issues a broker note on PureTech Health Plc 04 Dec 2017 | 08:30 Broker Forecast - Numis issues a broker note on PureTech Health Plc 30 Nov 2017 | 14:00 PureTech's resTORbio raises $40m 30 Nov 2017 | 09:45 PureTech expands collaboration network 29 Nov 2017 | 09:48 PureTech Health to present in New York 22 Nov 2017 | 09:29 Broker Forecast - Peel Hunt issues a broker note on PureTech Health Plc 31 Oct 2017 | 10:20 Broker Forecast - Numis issues a broker note on PureTech Health Plc 25 Sep 2017 | 11:30 PureTech wins US patent for speech analysis technology 20 Sep 2017 | 09:33 PureTech in exclusive licensing agreement with 3P Biotechnologies 19 Sep 2017 | 07:33 PureTech loss widens on higher R&D spend 30 Aug 2017 | 08:30 FLASH: PureTech makes $67.3m loss 30 Aug 2017 | 07:21 PureTech signs licensing agreement 29 Aug 2017 | 09:06 PureTech names new Executive Chairman of subsidiary 28 Jun 2017 | 14:22

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Tangible Assets
6.9
6.9
Intangible Assets & Goodwill
3.3
3.5
Investments & Other Non-Current Assets
131.6
0.2
Total Non-Current Assets
141.7
10.6
Inventory
0.0
0.0
Trade & Receivables
1.8
0.1
Cash & Receivables
72.7
63.0
Other Current Assets & Assets Held for Resale
123.7
225.1
Total Assets
339.9
298.8

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Short Term Liabilities
273.9
204.1
Long Term Liabilities
2.0
2.3
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
275.9
206.3

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Net Assets
64.0
92.4

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Share Capital
4.7
4.6
Minority Interests
-150.3
-85.3
Retained Earnings
-127.9
169.3
Share Premium Account
181.6
181.7
Other Equity
155.9
-177.9
Total Equity
64.0
92.4

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Cashflow from Operating Activities
-88.7
-58.0
Cashflow Before Financing
-5.0
-101.3
Increase / Decrease in Cash
9.7
-71.8

Income (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Turnover
2.5
4.4
Cost of Sales
0.0
0.0
Gross Profit
0.0
0.0
Operating Profit
-115.4
-73.9
Pre-Tax Profit
-70.7
-83.2
Profit / Loss for the Year
-70.7
-81.6
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.